SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

Search

UCB SA

Suletud

SektorTervishoid

160.1 1.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

156.6

Max

160.35

Põhinäitajad

By Trading Economics

Sissetulek

649M

857M

Müük

570M

3.4B

P/E

Sektori keskmine

28.896

56.602

Aktsiakasum

2.09

Dividenditootlus

0.9

Kasumimarginaal

25.498

Töötajad

9,052

EBITDA

704M

1.3B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.23% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.90%

2.45%

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-5.6B

30B

Eelmine avamishind

158.9

Eelmine sulgemishind

160.1

Uudiste sentiment

By Acuity

48%

52%

193 / 382 Pingereas Healthcare

UCB SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. mai 2025, 20:40 UTC

Omandamised, ülevõtmised, äriostud

FedEx Names CEO, Chairman for Planned Freight Spinoff

20. mai 2025, 00:00 UTC

Peamised uudised

America's Fiscal Situation Threatens the Good Mood on Wall Street -- WSJ

19. mai 2025, 23:48 UTC

Market Talk

Nikkei May Rise as Fears About Moody's U.S. Downgrade Ease -- Market Talk

19. mai 2025, 23:43 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

19. mai 2025, 22:33 UTC

Market Talk

Uranium Buyers Could Accelerate Restocking -- Market Talk

19. mai 2025, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Use Divestment Proceeds for Business Development Purposes

19. mai 2025, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Sell Stake for CNY4.15B

19. mai 2025, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Sell Stake to China Resources Land

19. mai 2025, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yuexiu Property to Sell 65% Stake in Beijing Haizhen Real Estate

19. mai 2025, 22:02 UTC

Tulu

Trip.com Group 1Q Rev $1.9B >TCOM

19. mai 2025, 22:02 UTC

Tulu

Trip.com Group 1Q Adj EPS 82c >TCOM

19. mai 2025, 22:02 UTC

Tulu

Trip.com Group 1Q EPS 84c >TCOM

19. mai 2025, 21:58 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

19. mai 2025, 21:58 UTC

Market Talk

Global Equities Roundup: Market Talk

19. mai 2025, 21:58 UTC

Market Talk

Automakers to Raise Prices by End of June, Toyota COO Says -- Market Talk

19. mai 2025, 21:50 UTC

Tulu

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19. mai 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: R. Brad Martin, Vice Chmn of the FedEx Corp. Bd of Directors, Agreed to Serve as Chmn of the Bd of FedEx Freight >FDX

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: Both Appointments Will Be Effective Upon Completion of the Previously Announced Separation of FedEx Freight From FedEx Corp. >FDX

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: Plans for the Spinoff, Which Is Expected to Occur by June 2026, Remain on Track >FDX

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: Announces Leadership for Independent FedEx Freight Co Upon Separation

19. mai 2025, 20:21 UTC

Omandamised, ülevõtmised, äriostud

FedEx: John A. Smith, Oper Chief, U.S. and Canada, of Federal Express, Has Been Selected as Pres and CEO of FedEx Freight >FDX

19. mai 2025, 20:20 UTC

Peamised uudised

Major U.S. Stock Indexes Finish Higher; Dollar Falls -- WSJ

19. mai 2025, 20:15 UTC

Omandamised, ülevõtmised, äriostud

U.S. Steel Stock Rises on Report of Better Nippon Offer. Why Trump Could Say 'Yes.' -- Barrons.com

19. mai 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. mai 2025, 19:59 UTC

Peamised uudised

JPMorgan CEO Dimon Still Intends to Step Down in Next Few Years. 'It's Up to the Board.' -- Barrons.com

19. mai 2025, 19:58 UTC

Market Talk

Estonia Redirects Ships After Russia Detains Greek Tanker -- Market Talk

19. mai 2025, 19:52 UTC

Market Talk

Imports Accelerate at Southern California Ports -- Market Talk

19. mai 2025, 19:16 UTC

Market Talk

Oil Futures Edge Up After Shaky Start -- Market Talk

19. mai 2025, 19:00 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Sanmina Shares Fall After Deal to Buy AMD's Newly Acquired Manufacturing Company

Võrdlus sarnastega

Hinnamuutus

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR  19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

1

Hoia

2

Müü

Sentiment

By Acuity

193 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.